Aptevo Therapeutics (APVO) Total Liabilities (2016 - 2025)
Aptevo Therapeutics (APVO) has disclosed Total Liabilities for 11 consecutive years, with $9.6 million as the latest value for Q3 2025.
- Quarterly Total Liabilities fell 10.46% to $9.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Sep 2025, down 10.46% year-over-year, with the annual reading at $10.8 million for FY2024, 14.14% down from the prior year.
- Total Liabilities hit $9.6 million in Q3 2025 for Aptevo Therapeutics, up from $9.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $58.2 million in Q1 2021 to a low of $9.1 million in Q2 2025.
- Historically, Total Liabilities has averaged $23.6 million across 5 years, with a median of $12.6 million in 2023.
- Biggest five-year swings in Total Liabilities: soared 484.17% in 2021 and later tumbled 77.06% in 2023.
- Year by year, Total Liabilities stood at $55.4 million in 2021, then tumbled by 70.68% to $16.2 million in 2022, then dropped by 22.29% to $12.6 million in 2023, then decreased by 14.14% to $10.8 million in 2024, then fell by 11.37% to $9.6 million in 2025.
- Business Quant data shows Total Liabilities for APVO at $9.6 million in Q3 2025, $9.1 million in Q2 2025, and $9.8 million in Q1 2025.